CollPlant Biotechnologies Ltd. (CLGN)
Summary
CollPlant Biotechnologies Ltd. (CLGN) Q4 2024 Earnings Call Transcript
CollPlant Biotechnologies Ltd. (NASDAQ:CLGN ) Q4 2024 Earnings Conference Call March 26, 2025 10:00 AM ET Company Participants Dory Kurowski - LifeSci Advisors Yehiel Tal - CEO Eran Rotem - Deputy CEO and CFO Conference Call Participants Swayampakula Ramakanth - H.C.
CollPlant Biotechnologies Ltd (CLGN) Q3 2024 Earnings Call Transcript
CollPlant Biotechnologies Ltd (NASDAQ:CLGN ) Q3 2024 Earnings Conference Call November 27, 2024 10:00 AM ET Company Participants Dory Kurowski - LifeSci Advisors Yehiel Tal - CEO Eran Rotem - Deputy CEO and CFO Operator Greetings, and welcome to the CollPlant Biotechnologies Third Quarter 2024 Earnings Call. At this time all participants are in a listen-only mode.
CollPlant (CLGN), Stratasys Initiate Study for Breast Implants
CollPlant (CLGN) and Stratasys announce the initiation of a pre-clinical study to focus on the ability of implants to grow natural breast tissue and completely degrade over time.
CollPlant Biotechnologies Ltd. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Anthony Scaramucci SkyBridge Capital II LLC | 64,000 | $34,304 | $22,355.2 | -$11,948.8 | -34.83% |
| RJ Rebecca Judd Pathstone Holdings, LLC | 57,000 | $44,560 | $19,374.3 | -$25,185.7 | -56.52% |
 Legacy Wealth Managment LLC/ID Legacy Wealth Managment LLC/ID | 23,179 | $15,424 | $7,417.28 | -$8,006.72 | -51.91% |
CollPlant Biotechnologies Ltd. (CLGN) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has CollPlant Biotechnologies Ltd. ever had a stock split?
CollPlant Biotechnologies Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Yehiel Tal CEO | NASDAQ (NMS) Exchange | 19516R107 CUSIP |
| IL Country | 39 Employees | - Last Dividend | - Last Split | 30 Jan 2018 IPO Date |
Overview
CollPlant Biotechnologies Ltd. is a pioneering company operating within the fields of regenerative and aesthetic medicine, with a strategic focus on the development of innovative solutions through three-dimensional (3D) bioprinting of tissues and organs. The company extends its presence across major markets including the United States, Canada, Israel, and Europe, enhancing its influence in the global healthcare landscape. The cornerstone of CollPlant's technological advancements is its proprietary plant-based genetic engineering technology utilized for the production of recombinant type I human collagen, which forms the basis of its diverse product portfolio. Initially established in 2004 and formerly known as CollPlant Holdings Ltd., the company underwent a rebranding to CollPlant Biotechnologies Ltd. in June 2019, thereby signifying a strategic realignment with its core operations and future aspirations. Its headquarters are located in Rehovot, Israel, positioning it within one of the leading centers for biotechnological research and development.
Products and Services
- BioInks for 3D Printing of Tissues and Organs: At the heart of CollPlant's offering is its BioInks, designed for the 3D printing of tissues and organs. This product enables the creation of complex biological structures, promising significant advancements in regenerative medicine and organ transplantation.
- Dermal Filler and Soft Tissue Fillers: To cater to the aesthetic medicine market, CollPlant has developed dermal filler and soft tissue fillers aimed at treating wrinkles and enhancing skin rejuvenation, tapping into the growing demand for non-invasive cosmetic procedures.
- 3D Bioprinted Breast Implants: A pioneering effort towards regenerative aesthetics, these implants are focused on the regeneration of breast tissue, offering an innovative solution for breast reconstruction and augmentation.
- Injectable Implants for Breast Tissue Regeneration: Complementing the breast implants, these injectable solutions promote the natural regeneration of breast tissue, proposing an alternative to traditional breast augmentation techniques.
- 3D Bioprinted Regenerative Soft Tissue Matrix: This product represents another application of CollPlant's 3D bioprinting technology, aimed at soft tissue repair and regeneration, showcasing the versatility of their bioprinting capabilities.
- VergenixSTR Soft Tissue Repair Matrix: Specifically designed for the treatment of tendinopathy, VergenixSTR is a soft tissue repair matrix that demonstrates CollPlant’s commitment to addressing a range of soft tissue injuries and conditions.
- VergenixFG Advanced Wound Care Product: Targeting a critical need in healthcare, VergenixFG is used for the treatment of deep surgical incisions and wounds, including those deriving from diabetes, venous and pressure ulcers, burns, bedsores, and other chronic wounds, providing an effective solution for advanced wound care management.
